Media Thread, page-14738

Looming patent cliff means that multiple big pharmaceutical companies are bracing themselves for biosimilar competition. This will typically lead to a decline in revenue for pharmaceutical companies while providing cost relief for patients with access to more affordable alternatives. It will however collectively costs big pharma hundred of billions of dollar of repeat sales if products not replaced with new and emerging treatment options. These companies have little choice but to renew or seek new relationships through acquisitions or partnerships to fast track the demands of their shareholders for revenue offset. This places clinical stage immuno-oncology companies like Imugene in a position of strength at the negotiation table when the time is right. Cut and paste and Goggle these keywords for additional information: top-10-drugs-with-patents-due-to-expire-in-the-next-5-year or follow link here : Top 10 Patent Expiry